CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing chimeric antigen receptor (CAR) T cells to target senescent cells for cancer treatment. By engineering T cells to clear these cells, the project aims to address challenges in cancer therapy and explore new treatment strategies for related diseases.
The adoptive transfer of T cells expressing CD19-directed chimeric antigen receptors (CARs) has yielded remarkable efficacy in patients with hematological B-cell malignancies. CARs are a class of synthetic receptors that reprogram T cell specificity, function and metabolism.
Engineered T cells are applicable in principle to other cancers and diseases, but clinical success will critically depend on further progress to overcome current limitations such as antigenic heterogeneity or impaired T cell…
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
